NSE
Suven Life Sciences LimitedSUVEN
Suven Life Sciences Limited is an NSE-listed company (SUVEN).
AI-generated overview — verify before relying on it.
Net institutional flow
No institutional deals
Institutional buyers
0 in / 0 out
High-impact filings
0 · tilt Neutral
Next corporate action
—
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | ATALREAL | +₹5.2 Cr | 162 | — | — | — | — |
| 2 | QUADFUTURE | +₹0.1 Cr | 148 | — | — | — | — |
| 3 | MOBIKWIK | +₹0.1 Cr | 83 | — | — | — | — |
| 4 | SUVENThis | — | — | — | — | — | — |
| 5 | MTNL | +₹0 Cr | 2 | — | — | — | — |
| 6 | GATECH | +₹0 Cr | 8 | — | — | — | — |
| 7 | IRMENERGY | −₹2.2 Cr | 328 | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
- 2026-06-17FilingSuven Life Sciences Limited has informed the Exchange regarding a press release dated Jun 17, 2026, titled "SuPress Release
- 2026-06-17FilingVenkateswarlu Jasti has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SecuritieShareholding Disclosure
- 2026-06-16FilingSuven Life Sciences Limited has informed the Exchange regarding a press release dated Jun 16, 2026, titled "SuPress Release
- 2026-06-12FilingSuven Life Sciences Limited has informed the Exchange regarding a press release dated Jun 12, 2026, titled "SuPress Release
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
- 2Press ReleaseNeutral
a press release dated Jun 17, 2026, titled "Suven Life Sciences announces Positive Topline results from Phase-2b clinical Proof-of-Concept trial of Ropanicant for the treatment of Major Depressive Disorder".
Source PDF → - 2Shareholding DisclosureNeutral
a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Source PDF → - 2Press ReleaseNeutral
a press release dated Jun 16, 2026, titled "Suven Life Sciences announces successful completion and topline results of First-in-Human (FIH) Phase-1 clinical study of SUVN-I6107, a Muscarinic M1 Positive Allosteric Modulator (M1-PAM) and its
Source PDF → - 2Press ReleaseNeutral
a press release dated Jun 12, 2026, titled "Suven Life Sciences announces three poster presentations on Samelisant (SUVN-G3031), including global Phase-3, AWAKE Narcolepsy Study at the SLEEP-2026 Annual Meeting being held at Baltimore, USA"
Source PDF →
No bulk/block deals for SUVEN in this window.
Results & transcripts
Financial results
None yet.
News & chatter on SUVEN
RSS News
0No recent news.
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.